Translational modifications to improve vaccine efficacy in an oral influenza vaccine

被引:11
作者
Bennett, Ewan [1 ]
Mullen, Alexander B. [1 ]
Ferro, Valerie A. [1 ]
机构
[1] Univ Strathclyde, Strathclyde Inst Pharm & Biomed Sci, Glasgow G4 0NR, Lanark, Scotland
基金
英国工程与自然科学研究理事会;
关键词
Oral vaccination; Influenza; IgG; IgA; Mucosal; STABILIZED VESICLES BILOSOMES; BILE-SALTS BILOSOMES; VIRUS-VACCINE; CROSS-PROTECTION; LIPID VESICLES; IMMUNIZATION; DELIVERY; LIPOSOMES; ANTIBODY; IMMUNITY;
D O I
10.1016/j.ymeth.2009.04.015
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Oral vaccination using protein antigens is complicated by the degradative effects of the inhospitable conditions in the gastrointestinal tract, such as low pH and digestive enzymes, nescessitating protection and effective delivery of the antigen. The bilosome is a lipid-based, vesicle delivery system incorporating bile salts, which is believed to protect the antigen from degradation, and has been shown to induce significant antibody responses when delivered orally with various vaccines. In translational research, from laboratory bench to industrial scale-up, it is necessary to optimise the manufacturing process in order to improve efficiency and simplify production, giving a more economical end-product. In this study we tested two simplified production methods (3-step and 1-step) along with two different storage methods (lyophilised and non-lyophilised), as well as looking at the effect of buffer pH. The formulations were assessed in a murine system for immunogenicity, alongside characterisation in terms of size and antigen entrapment, with the stability of these aspects assessed with respect to time. Both lyophilised and non-lyophilised 3-step formulations induced significant IgG1, IgG2a and IgA titres, with the lyophilised version showing stable size and antigen entrapment up to 9 months. (c) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:322 / 327
页数:6
相关论文
共 38 条
[21]   IMMUNIZATION AGAINST INFLUENZA IN HUMANS USING AN ORAL ENTERIC-COATED KILLED VIRUS-VACCINE [J].
LAZZELL, V ;
WALDMAN, RH ;
ROSE, C ;
KHAKOO, R ;
JACKNOWITZ, A ;
HOWARD, S .
JOURNAL OF BIOLOGICAL STANDARDIZATION, 1984, 12 (03) :315-321
[22]   Travel vaccines and elderly persons: Review of vaccines available in the United States [J].
Leder, K ;
Weller, PF ;
Wilson, ME .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (09) :1553-1566
[23]   CROSS-PROTECTION IN MICE INFECTED WITH INFLUENZA-A VIRUS BY THE RESPIRATORY ROUTE IS CORRELATED WITH LOCAL IGA ANTIBODY RATHER THAN SERUM ANTIBODY OR CYTO-TOXIC T-CELL REACTIVITY [J].
LIEW, FY ;
RUSSELL, SM ;
APPLEYARD, G ;
BRAND, CM ;
BEALE, J .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1984, 14 (04) :350-356
[24]   Oral delivery of tetanus toxoid using vesicles containing bile salts (bilosomes) induces significant systemic and mucosal immunity [J].
Mann, JFS ;
Scales, HE ;
Shakir, E ;
Alexander, J ;
Carter, KC ;
Mullen, AB ;
Ferro, VA .
METHODS, 2006, 38 (02) :90-95
[25]   Optimisation of a lipid based oral delivery system containing A/Panama influenza haemagglutinin [J].
Mann, JFS ;
Ferro, VA ;
Mullen, AB ;
Tetley, L ;
Mullen, M ;
Carter, KC ;
Alexander, J ;
Stimson, WH .
VACCINE, 2004, 22 (19) :2425-2429
[26]   HUMAN IMMUNE-RESPONSES TO INFLUENZA-VIRUS VACCINES ADMINISTERED BY SYSTEMIC OR MUCOSAL ROUTES [J].
MOLDOVEANU, Z ;
CLEMENTS, ML ;
PRINCE, SJ ;
MURPHY, BR ;
MESTECKY, J .
VACCINE, 1995, 13 (11) :1006-1012
[27]  
Ogra PL, 2001, CLIN MICROBIOL REV, V14, P641
[28]   Liposome-mediated DNA vaccination: the effect of vesicle composition [J].
Perrie, Y ;
Frederik, PM ;
Gregoriadis, G .
VACCINE, 2001, 19 (23-24) :3301-3310
[29]   Vaccine adjuvants: Current state and future trends [J].
Petrovsky, N ;
Aguilar, JC .
IMMUNOLOGY AND CELL BIOLOGY, 2004, 82 (05) :488-496
[30]   Neuraminidase-specific antibody responses to inactivated influenza virus vaccine in young and elderly adults [J].
Powers, DC ;
Kilbourne, ED ;
Johansson, BE .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 1996, 3 (05) :511-516